*See "Non-GAAP Financial Measures" above on slide 2. $90 $MM | We shop. You save. MA LTV | We shop. You save. 8 LTM 9/30/22 LTM 9/30/23 9 60,000 $MM | We shop. You save. l | | l $37 $38 $7 $9 Life Auto & Home 1Q23 1Q24 $5 $5 $2 $3 Life Auto & Home 1Q23 1Q24 11 12 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------|-------|--------|-------|----------------------|-------|------------|-------------|-------|--------- ...

Financial Data and Key Metrics - The company achieved stable and strong profitability in Q1 2024, marking seven consecutive quarters of improved operating results across all business segments [18] - Consolidated revenue for Q1 2024 was $233 million, with adjusted EBITDA at negative $11 million, representing a year-over-year improvement of over $16 million compared to Q1 2023 [54] - SelectRx surpassed 52,000 members, with healthcare services revenue exceeding senior revenues for the first time in company history [19] - Senior distribution business grew revenue by 16% year-over-year, with MA approved policies increasing by 17% to 98,000 [29][63] - Life and Auto & Home segments combined revenues were $47 million, up nearly 7% year-over-year, with adjusted EBITDA totaling nearly $9 million [47][44] Business Line Performance - SelectRx membership grew by over 60% year-over-year, reaching 52,000 members, driven primarily by Medicare Advantage interactions [67] - Healthcare services revenue grew by 50% year-over-year, driven by the maturation of the membership base and increased full-box utilization [5] - Senior distribution business saw a 22% decline in operating expense per policy, a 30% improvement in marketing expense per policy, and a 25% increase in agent close rates year-over-year [65] - Life business benefited from the adoption of the SwiftTerm Select product, while Auto & Home remained stable despite a challenging P&C insurance market [47] Market Performance - The company is well-positioned to serve all 50 states, with a single pharmacy system that is more efficient and integrated with automated fulfillment and shipping functions [58] - The Medicare Advantage market continues to show strong demand, with over 4 million Americans turning 65 each year, providing a long-term growth opportunity [40] - The company has seen deeper coordination with carriers, improving onboarding experiences and retention behavior [22] Strategic Direction and Industry Competition - The company’s strategy focuses on tenured agents, high-quality leads, and advanced technology tools to drive efficiency and policyholder persistency [20][21] - SelectRx is seen as a key differentiator, with the platform enabling differentiated customer acquisition and engagement, positioning the company at an advantageous intersection in the healthcare ecosystem [59] - The company is exploring additional market opportunities to leverage its platform for delivering value in the healthcare ecosystem [60] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the company’s preparation for the AEP and OEP seasons, with early results aligning with expectations [53] - The company expects to achieve attractive EBITDA margins in the low 20s for the senior distribution business in fiscal 2024 [32] - Management highlighted the importance of the healthcare services segment in offsetting seasonal expenses and driving future profitability [28] Other Important Information - The company emphasized its unique value proposition, combining Medicare Advantage distribution with tailored prescription drug delivery to drive higher patient medication adherence [25] - SelectRx’s revenue per member per month is more than 35% higher than the prior business, reflecting improved unit economics [24] - The company’s tenured agent retention remains strong, providing a key strategic advantage in the competitive Medicare Advantage market [55] Q&A Session Summary Question: Impact of regulatory changes on AEP performance - The company noted that regulatory changes, such as the 48-hour rule, had some impact but were in line with expectations, with no significant disruptions observed [34][69] - Management highlighted that the company’s alignment with carriers and focus on high-adherence solutions has been well-received, contributing to positive persistency and adherence metrics [77][71] Question: Growth trajectory and operational readiness for SelectRx - Management expressed confidence in SelectRx’s growth trajectory, expecting membership growth of 25% and healthcare services revenue growth of 50% for the year [5] - The company has scaled operations effectively, with customer satisfaction and NPS scores being strong indicators of operational readiness [70] Question: Outlook on P&C insurance market - The company acknowledged the challenging P&C insurance market but noted that carriers are adjusting underwriting practices, with the business continuing to perform well [80] Question: EBITDA cadence for fiscal 2024 - Management expects the EBITDA cadence to follow historical patterns, with healthcare services projected to achieve low single-digit EBITDA margins, improving as the business scales [74] Question: Plan design and shopping behavior - Management observed that plan features this year are similar to last season, with carriers focusing on maintaining critical consumer benefits, leading to stable shopping behavior [86][92]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR (Registrant's telephone number, including area code) (Former name, former address and former fiscal year, if changed since last report) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered pursuant to Section ...

Financial Data and Key Metrics Changes - In fiscal 2023, the company generated revenue of just over $1 billion and adjusted EBITDA of $74 million, representing a significant outperformance compared to original expectations [53][80] - Year-over-year revenue increased by 59% for the fourth quarter and 31% for the full year, driven by growth in SelectRx and improved efficiency in the core Senior business [21][80] - Adjusted EBITDA margin for the Senior segment was 26%, with a full-year adjusted EBITDA of $155 million at a margin of 26%, significantly better than the previous year [5][47] Business Line Data and Key Metrics Changes - SelectRx membership grew to nearly 50,000, doubling over the past year, with revenue growth of 260% compared to fiscal 2022 [18][60] - The Senior business saw a 13% decline in Medicare Advantage policy production year-over-year, but this was better than the expected 35% to 45% decline due to improved agent close rates and marketing efficiency [58][82] - The Life division delivered $23 million in adjusted EBITDA at a 16% margin, contributing to the overall profitability of the company [25] Market Data and Key Metrics Changes - The company noted a 63% increase in the percentage of revenues received in year one from carriers, up from 53% the previous year, indicating a shift towards high-quality policy volume [20] - The Medicare Advantage market remains favorable, with expectations for continued growth and stability in policyholder persistency [56][74] Company Strategy and Development Direction - The company aims to leverage its unique position as a central hub in the healthcare ecosystem to create additional revenue opportunities, similar to SelectRx [6][19] - The strategic redesign focused on improving cash flow and profitability, with plans to maintain a disciplined approach to policy production while enhancing operational efficiency [53][84] - Future initiatives will focus on specialized home care, specialty pharmacy, and remote patient interaction, aiming to provide convenience and adherence for seniors [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic redesign's effectiveness, which has led to improved operational and financial results [13][51] - The company anticipates a strong 2024 season, with expectations for consolidated revenue growth of 12.5% at the midpoint and adjusted EBITDA ranging from $80 million to $105 million [62] - Management highlighted the importance of maintaining a high-quality agent force and effective lead targeting to drive future growth [70][71] Other Important Information - The company achieved a cash EBITDA of $72 million for the year, indicating strong cash flow generation despite investments in growth initiatives [46][81] - The company has been recognized with the Patient-Centered Pharmacy Home accreditation, underscoring the quality of services provided to seniors [83] Q&A Session Summary Question: Thoughts on carrier plans and expectations - Management expressed excitement about the competitive nature of carrier plans, particularly for lower-income seniors, which aligns with the company's focus [9] Question: Growth expectations and market conditions - Management noted that increased shopping behavior among consumers could provide a tailwind for growth, especially for those eligible for special needs plans [36] Question: Capital deployment and debt management - Management indicated a focus on improving capital structure and reducing overall debt costs, with regular dialogue with term lenders [71] Question: Lead generation strategies for 2024 - Management emphasized a balanced approach to lead generation, focusing on high-quality leads and maintaining marketing efficiency despite new regulations [69]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-39295 (Commission File Number) SelectQuote, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiz ...

SelectQuote, Inc. (NYSE:SLQT) Q3 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Matthew Gunter - Chief Communications Officer and Investor Relations Timothy Danker - Chief Executive Officer Ryan Clement - Chief Financial Officer William Grant - Chief Operating Officer Robert Clay Grant - President Conference Call Participants Jonathan Yong - Credit Suisse Daniel Grosslight - Citigroup Inc. Ben Hendrix - RBC Capital Markets Operator Hello, everyone, and welcome to SelectQuote Thir ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-39295 (Commission File Number) Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required t ...

Financial Data and Key Metrics Changes - The company reported consolidated revenue of $319 million for the quarter, with adjusted EBITDA of $64 million, indicating strong performance ahead of expectations [10][97] - Senior revenue grew over 50% year-over-year to $224 million, with senior adjusted EBITDA margin reaching 37% [12][14] - Operating expense per approved policy declined by 41% year-over-year, contributing significantly to EBITDA outperformance [6][78] Business Line Data and Key Metrics Changes - The healthcare services segment, particularly Select Rx, saw a member growth of about 20% over the last quarter and 411% compared to a year ago, with over 39,000 members [4][5] - The volume of approved Medicare Advantage policies declined by 18% to 219,000, which was better than the original plan of a 35% to 45% decline [15][13] - The company achieved a significant reduction in marketing costs per approved policy, down 50%, driven by improved agent close rates and optimized marketing channels [25][23] Market Data and Key Metrics Changes - The company had a cash position of $96 million as of January 31, compared to $36 million as of December 31, indicating improved liquidity [11] - The annual enrollment period (AEP) was described as the heaviest cash use season, with the company positioned well to drive growth in cash-efficient profitability [10][47] Company Strategy and Development Direction - The overarching strategy focuses on optimizing unit and enterprise-level profitability and cash efficiency over growth, with a commitment to balance growth opportunities with profitability [26][48] - The company plans to slow growth in Select Rx members to prioritize profitability and cash flow, while still recognizing the significant market opportunity [5][22] - Strategic changes have been made to improve agent efficiency and marketing effectiveness, which are expected to be repeatable in future Medicare Advantage seasons [31][87] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to drive positive cash EBITDA for fiscal 2023, with expectations for continued improvement in profitability and cash efficiency [47][56] - The company noted stability in policyholder persistency and improved approval rates, which are critical for delivering predictable profit and growth [98][52] - Management emphasized the importance of maintaining a focus on cash and profitability, rather than solely on growth metrics [40][62] Other Important Information - The company has increased its full-year adjusted EBITDA outlook to a range of $5 million to $25 million, reflecting confidence in its strategic execution [93] - The strategic redesign has led to a significant improvement in cash efficiency, with the cash breakeven period for Medicare Advantage policies now just over two years [86][87] Q&A Session Summary Question: Comments on the broader marketing and revenue to CAC - Management highlighted improvements in revenue to customer acquisition costs, emphasizing a focus on unit economics and profitability [37] Question: LTV dynamics and future expectations - Management indicated that LTVs exceeded internal expectations for Q2 and are expected to remain at or above $875 for the full year, with positive trends in retention [62][60] Question: Liquidity needs and funding strategy - Management confirmed that the company is well ahead of its cash plan and is actively engaging with lenders for a more permanent capital structure solution [68]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-39295 (Commission File Number) SelectQuote, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3339273 (State or other j ...

SelectQuote, Inc. (NYSE:SLQT) Q1 2023 Results Conference Call November 3, 2022 8:00 AM ET Company Participants Matt Gunter - IR Tim Danker - CEO Ryan Clement - Interim CFO Bob Grant - President Bill Grant - COO Conference Call Participants Daniel Grosslight - Citigroup Jonathan Yong - Credit Suisse Meyer Shields - KBW Operator Welcome to SelectQuote’s First Quarter Earnings Conference Call. [Operator Instructions] It is now my pleasure to introduce Matt Gunter, SelectQuote Investor Relations. Mr. Gunter, yo ...